Erlotinib as salvage treatment after failure to first-line gefitinib in Non-Small Cell Lung Cancer

被引：0
|
作者：
Wong, King Yan Matthew [1 ]
Lo, Alvis [1 ,2 ]
Lam, Jamie [1 ]
Lam, Bing [1 ]
Ip, Mary S. [1 ]
Ho, James C. [1 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Ctr Hosp Conde Sao Januario, Dept Resp Med, Macao, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S719 / S719
页数：1
相关论文
共 50 条
  • [1] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Matthew K. Wong
    Alvis I. Lo
    Bing Lam
    W. K. Lam
    Mary S. Ip
    James C. Ho
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 1023 - 1028
  • [2] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Wong, Matthew K.
    Lo, Alvis I.
    Lam, Bing
    Lam, W. K.
    Ip, Mary S.
    Ho, James C.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1023 - 1028
  • [3] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    Song Zheng-bo
    Yu Yong-feng
    Chen Zhi-wei
    Lu Shun
    [J]. CHINESE MEDICAL JOURNAL, 2011, 124 (15) : 2279 - 2283
  • [4] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    SONG ZhengboYU YongfengCHEN Zhiwei and LU Shun Shanghai Lung Tumor Clinical Medical CenterChest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
    [J]. 中华医学杂志(英文版), 2011, (15) : 2279 - 2283
  • [5] Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
    Cho, Kyoung Min
    Keam, Bhumsuk
    Kim, Tae Min
    Lee, Se-Hoon
    Kim, Dong-Wan
    Heo, Dae Seog
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2015, 30 (06): : 891 - 898
  • [6] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment: Is there a rationale for a clinical trial?
    Salesi, Nello
    Di Cocco, Barbara
    Calabretta, Francesca
    Ciorra, Alida Armida
    Cirino, Crescenzo
    Cauchi, Carolina
    Pistillucci, Giorgio
    Sciacca, Venerina
    Rossi, Rosalinda
    Veltri, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [8] First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
    Lange, T
    Müller-Tidow, C
    Serve, H
    Hoffknecht, P
    Berdel, WE
    Thomas, M
    [J]. ONCOLOGY REPORTS, 2005, 14 (06) : 1539 - 1542
  • [9] Erlotinib in the first-line treatment of non-small-cell lung cancer
    D'Arcangelo, Manolo
    Cappuzzo, Federico
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
  • [10] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
12345